# Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

Study · id `cardio:ct-nct05360446` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05360446](<https://clinicaltrials.gov/study/NCT05360446>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05360446

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 610 participants.

## Technical summary

Registry record NCT05360446. Randomized; triple masking; primary purpose treatment. Start 2022-07-08 (actual); primary completion 2026-10-26 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 610 participants (enrolled count; ClinicalTrials.gov record NCT05360446, source copy `cardio:ctgov-nct05360446-2026-10-26`, retrieved 2026-10-31)
- Started: 2022-07-08 (actual) (ClinicalTrials.gov record NCT05360446, source copy `cardio:ctgov-nct05360446-2026-10-26`, retrieved 2026-10-31)
- Primary completion: 2026-10-26 (anticipated) (ClinicalTrials.gov record NCT05360446, source copy `cardio:ctgov-nct05360446-2026-10-26`, retrieved 2026-10-31)
- Completion: 2026-10-27 (anticipated) (ClinicalTrials.gov record NCT05360446, source copy `cardio:ctgov-nct05360446-2026-10-26`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Belgium; Brazil; Canada; Chile; China; France; Hungary; India; Ireland; Italy; Japan; South Korea; Spain; Switzerland; United Kingdom (ClinicalTrials.gov record NCT05360446, source copy `cardio:ctgov-nct05360446-2026-10-26`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05360446-2026-10-26`, retrieved 2026-10-31)

## The registry's words

- Brief title: Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
- Acronym: V-PLAQUE
- Condition: Coronary Artery Disease
- Intervention (Drug): Inclisiran sodium 300 mg
- Intervention (Drug): Placebo
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Inclisiran (`cardio:inclisiran`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: ad6e49679456d4f0548e868ab060202f568a93458d36eda94b5e0b1b4361e060
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
